SCHEMBL5757313

SCHEMBL5757313

CC(NC(=O)O)c1cc(N)ccn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
ADORA2A P29274 3/20 0.36
MAPK1 P28482 5/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.35
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35
GABRB2 P47870 1/20 0.35
GABRA4 P48169 1/20 0.35
GABRE P78334 1/20 0.35
GABRA6 Q16445 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6392481 0.75 PARP1 (0.49) ADORA2AMAPK1MEN1KMT2ACHRM4
SCHEMBL6164930 0.74 GABRP (0.39) KDM4CGABRPGABRDGABRA1GABRB1
Hydrochloric Acid SCHEMBL29100049 0.74 GABRP (0.35) ALOX5KDM4CMAPK1MEN1KMT2A
SCHEMBL6164927 0.74 GABRP (0.39) KDM4CGABRPGABRDGABRA1GABRB1
SCHEMBL293009 0.73 ASIC3 (0.41) MAPK1MEN1LMNAKMT2AASIC3
SCHEMBL22836727 0.70 CPN1 (0.49) MEN1LMNAKMT2A
SCHEMBL14065100 0.70 CPN1 (0.49) MEN1LMNAKMT2A
SCHEMBL3859307 0.70 CPN1 (0.49) MEN1LMNAKMT2A
SCHEMBL27854079 0.70 KDM4C (0.48) KDM4CMAPK1MEN1LMNAKMT2A
SCHEMBL27582427 0.69 ALDH1A1 (0.42) MAPK1MEN1LMNAKMT2AOPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0815100-B1 TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES SCHERING CORP (US) 2006-06-21 EP disclosed
US-20030055065-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases BISHOP W ROBERT (US) 2003-03-20 US disclosed
US-20020068742-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases BISHOP W ROBERT (US) 2002-06-06 US disclosed
US-6365588-B1 AS ANTINEOPLASTIC AGENT AND A POTENTIATING SCHERING CORPORATION 2002-04-02 US disclosed
US-6242458-B1 INHIBITING FARNESYL PROTEIN TRANSFERASE IN A HUMAN SCHERING CORPORATION 2001-06-05 US disclosed
US-5807852-A Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases SCHERING CORPORATION (US) 1998-09-15 US disclosed
US-5807853-A Tricyclic amide and urea compounds, useful inhibition of g-protein function and for treatment of proliferative diseases SCHERING CORPORATION (US) 1998-09-15 US disclosed
US-5719148-A FARNESYL-PROTEIN TRANSFERASE INHIBITORS SCHERING CORPORATION (US) 1998-02-17 US disclosed
US-5714609-A FORMING CHEMICAL INTERMEDIATE BY NITRATING SUBSTITUTED BENZO/5,6/CYCLOHEPTA/1,2-B/PYRIDINE WITH TETRABUTYLAMMONIUM NITRATE AND TRIFLUOROACETIC ANHYDRIDE IN SOLVENT AT REDUCED TEMPERATURE SCHERING CORPORATION (US) 1998-02-03 US disclosed
EP-0815100-A1 TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES SCHERING CORPORATION (US) 1998-01-07 EP disclosed
US-5700806-A FARNESYL PROTEIN TRANSFERASE ENZYME INHIBITOR, ANTITUMOR AGENTS SCHERING CORPORATION (US) 1997-12-23 US disclosed
US-5696121-A 4-(3-BROMO 8-CHLORO-6,11-DIHYDRO-5H-BENZO(5,6)CYCLOHEPTA(1,2B)PYRIDINE-11-YL)-N-(3 -PYRIDINYL)-1-PIPERAZINECARBOXIDE; ANTITUMOR AGENT; FARNESYL PROTEIN TRANSFERASE INHIBITOR SCHERING CORPORATION (US) 1997-12-09 US disclosed
WO-1996030363-A1 TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES SCHERING CORPORATION (US) 1996-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055065-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases RASGRP1, CCNA1, CCNA2 ALOX5 2586/4885KDM4C 4640/4885ADORA2A 2158/4885
US-20020068742-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases RASGRP1, CCNA1, CCNA2 ALOX5 2586/4885KDM4C 4640/4885ADORA2A 2158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.